306 related articles for article (PubMed ID: 32869188)
1. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.
Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M
Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
3. Alterations of E-cadherin, alpha-catenin and beta-catenin expression in neuroendocrine tumors of the gastrointestinal tract.
Li CC; Xu B; Hirokawa M; Qian Z; Yoshimoto K; Horiguchi H; Tashiro T; Sano T
Virchows Arch; 2002 Feb; 440(2):145-54. PubMed ID: 11964044
[TBL] [Abstract][Full Text] [Related]
4. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
5. Clusterin expression in gastrointestinal neuroendocrine tumours is highly correlated with location and is helpful in determining the origin of liver metastases.
Mourra N; Scriva A; Mansiaux Y; Gozlan S; Bennis M; Balaton A
Histopathology; 2014 Nov; 65(5):642-50. PubMed ID: 24807631
[TBL] [Abstract][Full Text] [Related]
6. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis.
Mia-Jan K; Munkhdelger J; Lee MR; Ji SY; Kang TY; Choi E; Cho MY
Tohoku J Exp Med; 2013 Apr; 229(4):301-9. PubMed ID: 23615455
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
9. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
[TBL] [Abstract][Full Text] [Related]
10. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations of GI-NECs involving three main signaling pathways.
Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.
Klöppel G
Visc Med; 2017 Oct; 33(5):324-330. PubMed ID: 29177160
[TBL] [Abstract][Full Text] [Related]
13. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
14. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
16. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
17. Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S; Vanoli A
J Clin Pathol; 2014 Nov; 67(11):938-48. PubMed ID: 25053544
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
19. INSM1 Is a Highly Specific Marker of Neuroendocrine Differentiation in Primary Neoplasms of the Gastrointestinal Tract, Appendix, and Pancreas.
McHugh KE; Mukhopadhyay S; Doxtader EE; Lanigan C; Allende DS
Am J Clin Pathol; 2020 May; 153(6):811-820. PubMed ID: 32128564
[TBL] [Abstract][Full Text] [Related]
20. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme.
Yin XN; Shen CY; Yin YQ; Chen HJ; Chen HN; Yin Y; Han LY; Chen JJ; Tang SM; Chen ZX; Zhang B
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e37-e44. PubMed ID: 28856815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
